Investor Relations Contact Us Careers
Nasdaq: FEMY
Innovative Solutions

Built to disrupt
women’s health.

From fertility to permanent contraception we are creating the future of office-based women’s healthcare delivered by OB/GYNs.

Our Solutions Investor Relations →
The Fertility Crisis

IVF is failing to address
the crisis in fertility.

In 2025, U.S. fertility rates dropped to another record low.

  • Too ExpensiveHigh cash pay requirement is insurmountable for most.
  • Fear of Surgery & DrugsHigh emotional toll prevents many women from pursuing.
  • Not Enough Infertility DoctorsLimited pipeline of new physicians further threatens future access.
  • Not Enough Fertility CentersToo few centers, concentrated in major cities.
U.S. fertility rate data collage
“FemaSeed offers an accessible, patient-centered approach that may help many individuals begin care sooner and with less complexity, and we are pleased to make it available as an early step in treatment.” Dr. Angela Silber, M.D.OB/GYN, Refuah Health Center, New York
Empowering OB/GYNs

The physician women
trust first.

Femasys is simplifying fertility care so OB/GYNs can take a more active role in delivering complete first-line fertility care in the office patients already know.

From Diagnosis Hers & his diagnostics
  • FemVue®
  • SpermVue™
To Treatment First-line insemination
  • FemaSeed®
  • FemSperm™

What this means for patients

She stays with her OB/GYN for timely, in-office care that is accessible and affordable.

Fertility Portfolio →
OB/GYN consulting with a patient
“I am proud to be at the forefront of shifting fertility care into the OB/GYN setting with an approach that is easily integrated into clinical practice, well tolerated by patients, and operationally straightforward for staff, including in-office sperm preparation for use with FemaSeed.” Dr. Finazzo, D.O.Downriver OBGYN, Trenton, MI
Aslyn, FemaSeed patient
Patient Spotlight

More women are looking
for options other than IVF.

“For us, the success rates were about the same as IVF for my age, so it gave us great hope knowing that we might get lucky trying something much more affordable and less invasive.”

Aslyn, 39  •  Florida  •  FemaSeed patient, 2026

Read Aslyn’s full story at The Ribbon Box →
U.S. Portfolio Pipeline Permanent Birth Control →

Unique platform technology.
Built to expand OB/GYN offerings.

Expanding women’s healthcare from first-line fertility solutions to the future of permanent birth control.

FemBloc Non-surgical permanent birth control

Women deserve more than surgery for permanent contraception. FemBloc offers a minimally invasive approach with no implant left behind for a natural solution.

FemBloc.com →
In the U.S.: Enrolling in final pivotal trial for U.S. approval.
ClinicalTrials.gov ↗
Outside the U.S.: FemBloc is approved in Europe and other select countries.
Information Highlights All News →

Stay informed.

Corporate Presentation

Investor Presentation with Key Opinion Leaders

Featuring clinical commentary from KOLs at HRC Fertility, Fertility Center of Las Vegas, and Stanford University Medical Center.

View Presentation
Press Release

Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

A streamlined, single-visit fertility workflow by combining sperm preparation and ITI.

Press Release →
Video

Dr. Bedient on FemaSeed®

A physician’s perspective on integrating FemaSeed into office-based fertility care.

Watch Now →
Podcast

From Lab to Life the Journey Behind Solving Women’s Healthcare

Podcast episode featuring Femasys CEO and Founder, Kathy Lee-Sepsick.

Listen Now →
Main Menu

Sign Up to Stay Informed

Join others on the fertility journey. We’ll send only what matters.

By submitting, you agree to receive communications from Femasys. See our Privacy Policy. You may unsubscribe at any time.